|
MCID: FNN001
|
Finnish Type Amyloidosis malady |
|
Sources: 17Genetics Home Reference, 22MalaCards See all sources Export this MalaCard |
Genetics Home Reference: Lattice corneal dystrophy type II is characterized by an accumulation of protein clumps called amyloid deposits in tissues throughout the body. The deposits frequently occur in blood vessel walls and basement membranes, which are thin, sheet-like structures that separate and support cells in many tissues. Amyloid deposits lead to characteristic signs and symptoms involving the eyes, nerves, and skin that worsen with age.17
MalaCards: Finnish Type Amyloidosis, also known as amyloidosis finnish type, is related to amyloidosis and hereditary amyloidosis. An important gene associated with Finnish Type Amyloidosis is GSN (gelsolin). The drugs acetylcysteine and colchicine and the compounds retinyl palmitate and thiamine have been mentioned in the context of this disorder. Affiliated tissues include skin. |
|
Sources: 6Disease Ontology, 43UMLS, 30NIH Rare Diseases, 16GeneTests, 33OMIM See all sources |
Aliases & Descriptions:
|
|
|
|
Sources: 4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 43UMLS, 28NDF-RT See all sources |
Approved drugs:Search CenterWatch for finnish type amyloidosis Drug clinical trials:Search ClinicalTrials for finnish type amyloidosis Search NIH Clinical Center for finnish type amyloidosis Search CenterWatch for finnish type amyloidosis Inferred drug relations via UMLS/NDF-RT:43 28 acetylcysteine, colchcine, colchicine |
|
Sources: 16GeneTests See all sources |
|
Sources: 22MalaCards See all sources |
MalaCards organs/tissues related to finnish type amyloidosis:22Skin
|
|
|
|
|
|
Sources: 1BioGPS See all sources |
![]() |
|
|
|
Sources: 32Novoseek , 18HMDB, 9DrugBank, 34PharmGKB See all sources |
Compounds related to finnish type amyloidosis according to GeneDecks:(show all 28)
|
|
Sources: 12Gene Ontology See all sources |
